GLP-1, GIP and glucagon: how metabolic peptide signals work
GLP-1, GIP and glucagon are peptide hormones that help coordinate metabolism. They are related signals, but they act through different receptors and do not do the same job.
2 min read · 3 sources→What is retatrutide, and how does a triple receptor agonist differ from tirzepatide?
Retatrutide is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. Tirzepatide targets GIP and GLP-1 receptors. The extra target is a mechanistic difference,…
2 min read · 3 sources→Semaglutide and tirzepatide: what is different, and what does comparative evidence show?
Semaglutide primarily activates the GLP-1 receptor. Tirzepatide activates GIP and GLP-1 receptors. Both have been studied clinically, but results and approved uses belong to specific…
2 min read · 3 sources→How scientists measure appetite, insulin sensitivity and metabolic change
There is no single “metabolism test” that answers every question. Researchers combine measurements of appetite, intake, glucose handling, energy expenditure, body composition and clinical…
2 min read · 4 sources→Metabolic adaptation, weight plateaus and the limits of animal studies
Weight change can slow as energy needs and behavior change. Metabolic adaptation is one contributor, not a diagnosis that can be made from a few scale readings. Animal experiments help…
3 min read · 4 sources→What EloraTZP can teach us about combination obesity trials
EloraTZP is an investigational combination of eloralintide and tirzepatide. Its scientific question is whether adding amylin-receptor activity to a dual GIP and GLP-1 approach improves…
2 min read · 2 sources→Comparing amylin and GLP 1 research without inventing a winner
Eloralintide and semaglutide belong in a comparison of biological strategies, but they should not be treated as interchangeable products. Eloralintide was developed as a selective…
2 min read · 2 sources→What an active comparator adds to eloralintide research
An active comparator makes a trial more useful by asking how a new approach performs against an existing medicine rather than only against placebo. The EloraTZP phase 2b program included…
2 min read · 2 sources→Eloralintide and retatrutide represent different research strategies
Eloralintide and retatrutide are often grouped together as emerging obesity medicines, but their research questions differ. Eloralintide is an amylin-receptor agonist. Retatrutide combines…
2 min read · 2 sources→From LY3841136 to eloralintide how a candidate is evaluated
LY3841136 is the development identifier associated with eloralintide. A code name helps track a compound through discovery and clinical research; it is not a quality certificate for…
2 min read · 2 sources→What CagriSema research adds beyond semaglutide alone
CagriSema combines cagrilintide and semaglutide in a clinical development program. Its central question is whether combining amylin-related activity with GLP-1 activity produces useful…
2 min read · 2 sources→Survodutide liver studies measure more than weight loss
Survodutide is being studied for metabolic disease through combined glucagon and GLP-1 receptor activity. Liver research asks questions that a weight-loss trial alone cannot answer. The…
2 min read · 2 sources→What retatrutide liver fat findings do not yet prove
Retatrutide liver research has examined changes in liver fat in a randomized phase 2a study. This is human evidence, but the endpoint must be described accurately: an improvement in an…
2 min read · 2 sources→Body recomposition research needs more than a scale
“Body recomposition” usually refers to changing fat and lean tissue, but the phrase can hide several different outcomes. Losing weight, reducing fat mass, preserving muscle and improving…
2 min read · 2 sources→Retatrutide and VK2735 require a fair clinical comparison
Retatrutide and VK2735 are both being developed for metabolic disease, but their mechanisms and evidence timelines differ. Retatrutide combines GIP, GLP-1 and glucagon receptor activity.…
2 min read · 2 sources→How peptide medicines fit into diabetes evidence
Peptide-based medicines have established roles in diabetes, but the category includes products with different mechanisms and indications. Insulin and GLP-1-related medicines should not be…
2 min read · 2 sources→Semaglutide Evidence Belongs to a Product and a Population
Semaglutide is a GLP-1 receptor agonist with approved medicines, but the molecule's name does not describe one interchangeable product. The formulation, approved indication and population…
2 min read · 1 source→Pemvidutide Research Connects Weight and Liver Outcomes
Pemvidutide is being studied as a dual GLP-1 and glucagon receptor agonist. Its research program illustrates why metabolic drug trials should be read by disease and endpoint rather than…
2 min read · 2 sources→Orforglipron Shows Why GLP 1 Drugs Are Not All Peptides
Orforglipron acts at the GLP-1 receptor but is a nonpeptide small molecule. That distinction is useful: receptor target and molecular class describe different features of a medicine. A drug…
2 min read · 2 sources→Amycretin and Zenagamtide Refer to an Evolving Research Program
Amycretin is the earlier name used in studies of a candidate now described as zenagamtide. Naming matters when searching the literature: using only the older name can miss newer reports,…
2 min read · 2 sources→Retatrutide and Mazdutide Need a Trial Based Comparison
Retatrutide and mazdutide engage overlapping metabolic pathways, but they are different molecules with different development histories. Retatrutide targets GIP, GLP-1 and glucagon…
2 min read · 4 sources→5 Amino 1MQ and the Gap Between Mouse Metabolism and Human Treatment
5 amino 1MQ is a small molecule investigated as an inhibitor of nicotinamide N-methyltransferase, usually abbreviated NNMT. It is not a peptide. Keeping the chemical category correct helps…
2 min read · 3 sources→CagriSema and Retatrutide Require Different Evidence Questions
CagriSema and retatrutide illustrate two approaches to investigating obesity treatment. CagriSema combines cagrilintide with semaglutide. Retatrutide is a single investigational molecule…
2 min read · 3 sources→Comparing Survodutide Retatrutide and Tirzepatide Without a False Ranking
Three compounds often grouped together in metabolic research do not have identical targets or regulatory status. Tirzepatide acts at GIP and GLP-1 receptors. Survodutide is investigated as…
2 min read · 4 sources→Facial Changes During Weight Loss Need Better Evidence Than Peptide Promises
The phrase Ozempic face is a popular description, not a precise diagnosis. When someone's appearance changes during weight loss, a photograph alone cannot determine the contribution of fat…
2 min read · 3 sources→Fat Loss Evidence Should Be Organized by Indication and Outcome
Fat loss is not a single clinical outcome. A study may measure body weight, total fat mass, visceral fat or a disease complication associated with obesity. Those measures can move…
2 min read · 4 sources→Retatrutide and Tirzepatide Require Different Evidence Labels
Retatrutide and tirzepatide are related research topics, but their regulatory and clinical records should be presented separately. Tirzepatide is the active ingredient in approved…
2 min read · 3 sources→Read Tirzepatide Evidence by Indication and Outcome
Tirzepatide research covers several clinical questions, and the answer to one should not be substituted for another. An obesity trial, a diabetes trial and an obstructive sleep apnea trial…
2 min read · 2 sources→MOTS-c: From Mitochondrial Signaling to Testable Clinical Questions
MOTS-c is studied as a mitochondrial-derived signaling peptide. The discovery research examined cellular metabolism and animal physiology, including effects in mouse models of diet-related…
2 min read · 1 source→Retatrutide Results: Read the Published Analysis, Not the Largest Headline
Retatrutide's evidence base changed in 2026, so summaries limited to its 2023 phase 2 trial are incomplete. TRIUMPH-1 included adults without diabetes who had obesity or overweight with at…
2 min read · 3 sources→Weight-Management Medicines and Research Candidates Belong in Separate Groups
A list of best weight-loss peptides can mix approved medicines, investigational candidates and unrelated chemicals as though they are interchangeable choices. A more useful overview groups…
2 min read · 4 sources→Compare Semaglutide, Tirzepatide and Retatrutide Without a League Table
Semaglutide, tirzepatide and retatrutide are often displayed in a single weight-loss ranking. That presentation can conceal differences in product approval, receptor targets, patient…
2 min read · 3 sources→